RORocio Olivera-Salazar

Rocio Olivera-Salazar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rocio Olivera-Salazar has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Current perspectives of CAR-T cells therapy in peritoneal carcinomatosis

    by Siyuan Qian-Zhang, Víctor Domínguez-Prieto, Diego Romero-Triana, Rocio Olivera-Salazar, Pedro Villarejo-Campos

  • SEPTIN9 Gene Methylation Ratio as Follow‐Up Biomarker in Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

    by Víctor Domínguez‐Prieto, Rocío Olivera‐Salazar, Miguel León‐Arellano, Luz Vega‐Clemente, Rocío Barrueco‐Gutiérrez, Cristina Caramés, Eva Ruiz‐Hispán, Raquel Fuentes‐Mateos, Diana Isabel Rosero‐Rodríguez, Ignacio Mahillo‐Fernández, et al.

    Background: There are not reliable biomarkers for the assessment of tumor response to total neoadjuvant therapy (TNT) and the early detection of local regrowth or systemic relapse in patients with locally advanced rectal cancer (LARC). Our aim is to evaluate the utility of SEPTIN9 methylation ratio (SEPT9mr) for prediction and assessment of tumor response to TNT and for early diagnosis of local regrowth and systemic metastases in patients with LARC. Methods: Patients with LARC undergoing TNT were prospectively included. SEPTIN9 methylation status gene in plasmatic cfDNA was determined by ddPCR and expressed as SEPT9mr at 3 times: pre‐treatment, evaluation of tumor response and follow‐up. Association between pre‐treatment SEPT9mr, tumor response to TNT and metastatic risk was explored. Association between SEPT9mr variation between samples and tumor response to TNT, local regrowth and systemic metastases was also explored. Results: Sixty patients were included. Pre‐treatment SEPT9mr ( p = 0.004) significantly associated with tumor response to TNT, but not with metastatic risk during follow‐up ( p = 0.289). Variation of SEPT9mr during TNT did not significantly associate with tumor response to TNT ( p = 0.130). Variation of SEPT9mr during follow‐up did not associate with the development of local regrowth ( p = 0.533) but significantly associated with the development of systemic metastases ( p = 0.026). Conclusion: Pre‐treatment SEPT9mr can predict tumor response to TNT, but not the metastatic risk during follow‐up. Variation of SEPT9mr between samples seems to be useful for early detection of systemic metastases during follow‐up but not for evaluation of tumor response to TNT or detection of local regrowth.

  • Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review

    by Susana Olmedillas-López, Rocío Olivera-Salazar, Mariano García-Arranz, Damián García-Olmo

    In the era of personalized medicine and targeted therapies for the management of patients with cancer, ultrasensitive detection methods for tumor genotyping, such as next-generation sequencing or droplet digital polymerase chain reaction (ddPCR), play a significant role. In the search for less invasive strategies for diagnosis, prognosis and disease monitoring, the number of publications regarding liquid biopsy approaches using ddPCR has increased substantially in recent years. There is a long list of malignancies in which ddPCR provides a reliable and accurate tool for detection of nucleic acid-based markers derived from cell-free DNA, cell-free RNA, circulating tumor cells, extracellular vesicles or exosomes when isolated from whole blood, plasma and serum, helping to anticipate tumor relapse or unveil intratumor heterogeneity and clonal evolution in response to treatment. This updated review describes recent developments in ddPCR platforms and provides a general overview about the major applications of liquid biopsy in blood, including its utility for molecular response and minimal residual disease monitoring in hematological malignancies or the therapeutic management of patients with colorectal or lung cancer, particularly for the selection and monitoring of treatment with tyrosine kinase inhibitors. Although plasma is the main source of genetic material for tumor genomic profiling, liquid biopsy by ddPCR is being investigated in a wide variety of biologic fluids, such as cerebrospinal fluid, urine, stool, ocular fluids, sputum, saliva, bronchoalveolar lavage, pleural effusion, mucin, peritoneal fluid, fine needle aspirate, bile or pancreatic juice. The present review focuses on these “alternative” sources of genetic material and their analysis by ddPCR in different kinds of cancers.